- Home
- POAI vs KZIA Comparison
POAI vs KZIA Comparison
Compare POAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- KZIA
- Stock Information
- Founded
- POAI 2002
- KZIA 1994
- Country
- POAI United States
- KZIA Australia
- Employees
- POAI N/A
- KZIA N/A
- Industry
- POAI Industrial Specialties
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- KZIA Health Care
- Exchange
- POAI Nasdaq
- KZIA Nasdaq
- Market Cap
- POAI 7.8M
- KZIA 9.0M
- IPO Year
- POAI N/A
- KZIA 1999
- Fundamental
- Price
- POAI $0.89
- KZIA $7.82
- Analyst Decision
- POAI Hold
- KZIA Strong Buy
- Analyst Count
- POAI 1
- KZIA 2
- Target Price
- POAI N/A
- KZIA $14.00
- AVG Volume (30 Days)
- POAI 158.1K
- KZIA 19.7K
- Earning Date
- POAI 08-13-2025
- KZIA 06-05-2025
- Dividend Yield
- POAI N/A
- KZIA N/A
- EPS Growth
- POAI N/A
- KZIA N/A
- EPS
- POAI N/A
- KZIA N/A
- Revenue
- POAI $1,664,696.00
- KZIA $1,549,158.00
- Revenue This Year
- POAI $486.27
- KZIA N/A
- Revenue Next Year
- POAI $65.50
- KZIA $49.25
- P/E Ratio
- POAI N/A
- KZIA N/A
- Revenue Growth
- POAI 71.65
- KZIA 248983.08
- 52 Week Low
- POAI $0.55
- KZIA $2.86
- 52 Week High
- POAI $3.06
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- POAI 53.17
- KZIA 50.14
- Support Level
- POAI $0.85
- KZIA $7.52
- Resistance Level
- POAI $0.91
- KZIA $8.33
- Average True Range (ATR)
- POAI 0.05
- KZIA 0.64
- MACD
- POAI 0.00
- KZIA 0.04
- Stochastic Oscillator
- POAI 42.93
- KZIA 67.54
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.